ClinicalTrials.gg
No longer availableNCT03433807Updated Apr 21, 2023

Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

An expanded access record providing Idebenone in Duchenne Muscular Dystrophy, sponsored by Santhera Pharmaceuticals. No longer available at 12 sites in United States. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Santhera Pharmaceuticals · Expanded access

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
8 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 61 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Other kind
5 of 233
none open now
Registered
126th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is one of 5 of another kind, and was the 126th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 8 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • idebenone, DMD, Duchenne
04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of DMD (severe dystrophinopathy) and clinical features consistent of typical DMD at diagnosis (i.e., documented delayed motor skills and muscle weakness by age 5 years) and who in the opinion of the Treating physician would benefit from treatment with idebenone. DMD should be confirmed by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e., absent or \<5% of normal) on Western blot or immunostaining.
  • Minimum 8 years old at Prescreening.
  • PEF or FVC ≤80% and >25% of predicted value based on most recent assessment noted in the patient's medical record and subsequently confirmed at the Enrollment Visit.
  • Able to understand program requirements and swallow program medication.
  • Signed and dated Form (to be obtained at the Enrollment Visit from patient or parent/legal guardian (if applicable) prior to performing any program-specific procedures and dispensing idebenone to the patient).

Exclusion criteria

Exclusion Criteria:

  • Eligible for and able to participate in an ongoing clinical trial of idebenone.
  • Is at high-risk of a fatal outcome from lung infection and/or advanced cardiomyopathy in the opinion of the Treating physician.
  • Known moderate or severe impairment of hepatic function or severe impairment of renal function.
  • Prior or ongoing medical condition or laboratory abnormality which in the Treating physician's opinion may put the patient at significant risk or may interfere significantly with the patient's participation in the program.
  • Abuse of drugs or alcohol, which in Treating physician's opinion would interfere with the compliance to treatment.
  • Known individual to idebenone or to any of the ingredients/ of the program medication.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • 900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)

06

Where to request access

12 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kennedy Krieger
    Baltimore, Maryland 21287, United States
  • Columbia University Pediatric Neuromuscular Center
    New York, New York 10032, United States
  • Carolina's Healthcare System
    Charlotte, North Carolina 28207, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Virginia Children's Hospital
    Charlottesville, Virginia 22904, United States
  • St. Luke's Rehabilitation Institute
    Spokane, Washington 99202, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT03433807
Responsible party
Sponsor
First posted
Feb 15, 2018
Last update
Apr 21, 2023
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion